Delivering psilocybin via microneedle patch unlocks potential for desired dosage forms and pharmacokinetic profiles for improved safety and effectiveness. Completing microneedle patch research programs with other psychedelics before year-end. Pursuing Phase 2 clinical studies in 2022 with psilocybin and notable psychedelics. TORONTO, Nov. 11, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd.


Previous articlePTSF84 – A Brief Check-in From Wonderland
Next articlePsychedelic Bulletin: Deconstructing COMPASS Pathways’ Phase 2b Results